Efficacy and Safety of Lorlatinib via Early- or Expanded-Access Programs in TKI-Refractory ALK+ or ROS1+ NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology